This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Mozambique

2. **Grant number:** 17-MOZ-32a-X

3. **Date of Decision Letter:** 7 April 2017

4. **Date of the Partnership Framework Agreement:** 06 December 2013

5. **Programme title:** Injection Safety Devices

6. **Programme duration:** 2017

7. **Programme Budget (indicative):** (subject to the terms of the partnership framework agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2017</th>
<th>Total(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>305,000</td>
<td>305,000</td>
</tr>
</tbody>
</table>

8. **Indicative Annual Amounts:**

   **TOTAL** Injection Safety Devices to be purchased with Gavi funds in each year

   - Number of AD syringes: 5,950,500
   - Number of re-constitution syringes: 101,100
   - Number of safety boxes: 66,625
   - **Annual Amounts for Injection Safety Devices for all Gavi vaccines (US$):** 305,000

   Injection Safety Devices to be purchased with Gavi funds in each year, **by type of support**

   **New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine**

   - Number of AD syringes: 2,844,400
   - Number of safety boxes: 31,300
   - **Annual Amounts for Injection Safety Devices for Vaccine (US$):** 143,500

   **New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine**

   - **2017**

---

\(^1\) This does not include vaccines.

\(^2\) This is the entire duration of the Programme.

\(^3\) This is the total amount endorsed by Gavi for the entire duration of the Programme.
<table>
<thead>
<tr>
<th>New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, Routine</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>905,200</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>9,975</td>
</tr>
<tr>
<td>Annual Amounts for Injection Safety Devices for Vaccine (US$)</td>
<td>46,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Routine</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>350,300</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>101,100</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>4,975</td>
</tr>
<tr>
<td>Annual Amounts for Injection Safety Devices for Vaccine (US$)</td>
<td>22,000</td>
</tr>
</tbody>
</table>

9. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

10. **Self-procurement:** Not applicable

11. **Co-financing obligations:**
   Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,
**On behalf of Gavi**

Hind Khatib-Othman
Managing Director, Country Programmes
7 April 2017